Neuregen Biotechnology Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$14.7M
- Investors
-
6
Neuregen Biotechnology General Information
Description
Developer of biopharmaceutical drugs designed to apply in vivo cell transdifferentiation for treating neurological tumors and degenerative diseases. The company offers proprietary reprogramming technology that avoids stem cell stages and minimizes immune rejection, enabling patients with eye disorders and brain cancers to access novel therapeutic drugs.
Contact Information
Corporate Office
- Unit E613, 5th Floor, Le Orange Plaza, Phase II Biomedical Industrial Park, Number 218
- Sangtian Street, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Unit E613, 5th Floor, Le Orange Plaza, Phase II Biomedical Industrial Park, Number 218
- Sangtian Street, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
Neuregen Biotechnology Timeline
Neuregen Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 21-May-2026 | $14.7M | Completed | Generating Revenue | ||
| 3. Early Stage VC | 01-Jan-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 05-Jan-2024 | $1.57M | Completed | Generating Revenue | ||
| 1. Seed Round | 15-Feb-2022 | $1.57M | $1.57M | Completed | Startup |
Neuregen Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuregen Biotechnology Patents
Neuregen Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021228050-A1 | Method for inducing glial cells transdifferentiation into functional neurons, and application thereof | Inactive | 12-May-2020 |
Neuregen Biotechnology Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| SB China Venture Capital | Venture Capital | Minority | ||
| Wuhan Hi-Tech | Government | Minority | ||
| Shanghai Biomedical Public Technology | Corporation | Minority | ||
| Shanghai Science & Technology Investment | Venture Capital | Minority | ||
| Wuhan Institute of Biotechnology | Government | Minority |
Neuregen Biotechnology FAQs
-
When was Neuregen Biotechnology founded?
Neuregen Biotechnology was founded in 2021.
-
Where is Neuregen Biotechnology headquartered?
Neuregen Biotechnology is headquartered in Suzhou, China.
-
What industry is Neuregen Biotechnology in?
Neuregen Biotechnology’s primary industry is Drug Discovery.
-
Is Neuregen Biotechnology a private or public company?
Neuregen Biotechnology is a Private company.
-
What is Neuregen Biotechnology’s current revenue?
The current revenue for Neuregen Biotechnology is .
-
How much funding has Neuregen Biotechnology raised over time?
Neuregen Biotechnology has raised $30M.
-
Who are Neuregen Biotechnology’s investors?
SB China Venture Capital, Wuhan Hi-Tech, Shanghai Biomedical Public Technology, Shanghai Science & Technology Investment, and Wuhan Institute of Biotechnology are 5 of 6 investors who have invested in Neuregen Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
